NCT02295865View on ClinicalTrials.gov

A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

November 17, 2014

Primary Completion Date

March 11, 2016

Study Completion Date

March 11, 2016

Conditions
Psoriasis
Interventions
DRUG

JNJ-38518168 60 mg

Two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, orally, once daily.

DRUG

JNJ-38518168 30 mg

One tablet of JNJ-38518168, 30 mg, orally, once daily.

DRUG

JNJ-38518168 3 mg

One tablet of JNJ-38518168, 3 mg, orally, once daily.

DRUG

Placebo

Matching Placebo either 30 mg tablet or 3 mg tablet will be administered orally.

Trial Locations (13)

Unknown

Los Angeles

Santa Monica

Atlanta

Indianapolis

Plainfield

Louisville

Portland

Johnston

San Antonio

Spokane

Bydgoszcz

Lodz

Warsaw

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02295865 - A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis | Biotech Hunter | Biotech Hunter